Web16 de nov. de 2024 · Methods. In this open-label study (NCT01712009), women ≥ 18 years of age with newly diagnosed stage I–III breast cancer and an ECOG performance status ≤ 2 who were planning ≥ 4 cycles of adjuvant or neoadjuvant chemotherapy with pegfilgrastim support starting in cycle 1 were randomized 1:1:1 to receive naproxen, loratadine, or no … Web1 de fev. de 2024 · The exact mechanism for G-CSF–induced bone pain is not well understood, but research suggests that histamine release may play a role. Despite scant literature on antihistamine use in the management of G-CSF–induced bone pain, oncologists often prescribe loratadine, off-label, as prophylaxis for G-CSF–induced …
Loratadine - StatPearls - NCBI Bookshelf
Web1 de jul. de 2024 · Severe bone pain may not respond to acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, or dose reduction of the G-CSF agent. A study … Web18 de mar. de 2015 · Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days. Cycle 2 and 4: Placebo by mouth … dogwood services
Ask the Expert July August 2015 - Practical Pain Management
Web19 de fev. de 2016 · Purpose Bone pain is a common side effect of pegfilgrastim and can interfere with quality of life and treatment adherence. This study investigated the impact of antihistamine prophylaxis on pegfilgrastim-induced bone pain. Methods This is a two-stage enrichment trial design. Patients receiving an initial dose of pegfilgrastim after … Web28 de fev. de 2024 · Loratadine was associated with fewer treatment-related AEs and discontinuations than naproxen. Given its tolerability, its ease of administration, and its … WebThere are four main causes of G-CSF related bone pain: bone marrow quantitative and qualitative expansion, peripheral nociceptor sensitization to nociceptive stimuli, modulation of immune function and direct effect on bone metabolism. fairford howdens